Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacokinetic Boosting of Osimertinib in Patients With Non-small Cell Lung Cancer.

NCT03858491 is registered in ClinicalTrials.gov with Academisch Ziekenhuis Maastricht as lead sponsor.

NCT NCT03858491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03858491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacokinetic Boosting of Osimertinib in Patients With Non-small Cell Lung Cancer.
Lead sponsor
Academisch Ziekenhuis Maastricht
Phase
Phase 1
Overall status
Completed
Start date
November 1, 2020
Completion date
December 31, 2021
Enrollment
11 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer